Industry Secrets Concerning Trametinib That Happily Surprised Me

The median time to start of therapy was 12 days (range, 11�C14 days). For the entire cohort (n = 36), there were 23 (64%) males and the median age was 75 years (range, 64�C88 years). Only 6 (17%) patients were younger than 70 years of age and 22% of patients were older than 80 years of age. The MGMT promoter was found to be unmethylated in 31 of 36 (86%) patients. Fourteen (39%) http://www.selleckchem.com/products/MDV3100.html patients had newly diagnosed AML, 83% (30/36) had an ECOG performance status of 0-1 and a hematopoietic cell transplantation comorbidity index (HCT-CI) between 0-2. No patients with secondary AML (s-AML) had a mMGMT promoter. Median WBC count at presentation was 1.9 �� 103/��L and only 17% (6/36) of patients had a WBC >10 �� 103/��L. Intermediate (normal karyotype, n = 16) or unfavorable risk karyotype was found in 34/36 patients (94%) and FLT3-ITD, FLT3-TKD, NPM1 or CEPBA mutations were uncommon (Table I). IDH1 (R132) and IDH2 (R140) mutations were found in two and three patients, respectively. MSI was not detected in any of the 36 patients in this study. No differences were noted between the http://www.selleck.cn/products/pd-1-pd-l1-inhibitor-2.html baseline characteristics of patients with mMGMT versus unMGMT promoter (Table I). The ORR for the entire cohort was 36% including 30% CR plus CRi (Table II). All responses were noted after the first induction cycle. There were five (14%) patients who died while in aplasia prior to response assessment. When stratified by the MGMT methylation, overall and complete response rates were statistically similar in patients with mMGMT versus unMGMT promoter (60% vs. 32%) and 40% vs. 19%, respectively. No differences in the CR/CRi rate were noted among patients with de novo, secondary or relapsed AML (21% vs. 28% vs. 40% P = 0.24). As the incidence of induction deaths (ID) were similar in both groups, apparent lower overall response rates were primarily caused by a higher rate of resistant disease in unMGMT promoter group (51% vs. 20%). No differences in the median age, type of AML, MGMT promoter methylation http://www.selleckchem.com/products/gsk1120212-jtp-74057.html status, ECOG performance status, or molecular markers were noted between responders and nonresponders (data not shown). However, responding patients were more likely to have a normal karyotype (61% vs. 35%, P = 0.3) and lower risk HCT-CI scores (100% vs. 65%, P = 0.2). Finally, no significant differences in the rate of OR, ID, and RD (resistant disease) were noted between different types of AML (de novo, relapsed, or s-AML) (data not shown). Driven by the observation that >80% of responders had a baseline bone marrow blast counts